Navigation Links
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
Date:10/21/2013

of this single agent Phase I study are encouraging and further clinical development of ME-344 is warranted."

A copy of yesterday's poster presentation, entitled "ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study," is now available at www.meipharma.com.

ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Dose limiting toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy. Other medically significant adverse events observed in single patients included angina and QTc prolongation at the 10 mg/kg dose.

"We are encouraged by the results from this first-in-human study of ME-344," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "Not only did the trial show evidence of clinical activity, but the primary dose limiting toxicity was consistent with the proposed mechanism of action of ME-344, namely mitochondrial inhibition, suggesting on-target activity. Based on these findings, we are now actively preparing for a Phase Ib clinical trial of ME-344 in combination with Hycamtin® (topotecan) in small cell lung cancer and ovarian cancer, which we expect to initiate during the second quarter of 2014."

The Phase Ib trial will be designed to evaluate the safety and tolerability of ME-344 in combination with Hycamtin® in a total of 45 patients with either small cell lung cancer or ovarian cancer. Hycamtin® is a chemotherapy approved by the U.S. Food & Drug Administration for the treatment of small cell lung cancer and ovarian cancer, as well as cervical cancer.

About ME-344
ME-344 is MEI Pharma's isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause caspase-independent
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
2. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
3. ePharmaSolutions Wins Major Award for Life Sciences Industry Innovation
4. In Q1 Public Biopharmas Shift Fundraising into Overdrive
5. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
6. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. MEI Pharmas Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
11. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... GRC 17536, has shown positive data in a Phase ... diabetic neuropathy , Glenmark Pharmaceuticals ... Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown ... controlled, multi-centre, proof of concept study conducted on 138 ...
(Date:9/17/2014)...  Members of the physician IT team at ... today that the enterprise is working with ... capabilities and provide immediate cluster fail over in ... the Dicom Systems enterprise imaging solutions will be ... more effectively deliver the right images to the ...
(Date:9/17/2014)... 2014 An analysis done by the CVS ... (sofosbuvir), a new and expensive treatment for Hepatitis C ... last several months (May through August 2014) there has ... utilization. This suggests another surge of patients will begin ... similar efficacy and shorter duration are introduced in the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Event for Congressional Members and Staff Will Focus on Advances ... Research and Treatment of Lung Cancer in ... CTIC; MTAX:), along with the Society for Women,s Health,Research, the ... "Lung Cancer: Being Female Matters to Research," on,Capitol Hill to ...
... in cSSSI, CAMBRIDGE, Mass., Sept. 13 ... Phase 2 trial,investigating the safety and efficacy of ... of Complicated Skin and Skin Structure,Infections (cSSSI), or ... positive infections. This Phase 2 study is ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 2Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 3
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... member of the therapeutic care team that is making a ... and around the world: dogs. , “Studies show ... and stress levels in recovering addicts,” commented Best Drug Rehabilitation’s ...
(Date:9/17/2014)... gene manipulation these sound like the ideas ... they are components of an exciting new approach ... animal models of metastatic prostate cancer, scientists at ... of Molecular Medicine and Johns Hopkins Medical Institutions ... approach that could revolutionize doctors, ability to see ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Exposure in the womb to household chemicals known as ... asthma, Columbia University researchers reported in a new study. ... of developing asthma between age 5 and 11 if ... of two phthalates (pronounced thal-ates), the researchers found. The ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... breast density and its implication on the risks of breast ... has brought to the fore, the key challenges involved in ... revealed that, those with dense breasts were five times more ... with fatty tissue in the breasts. , ,Dense breasts ...
... Fat tissue around the abdomen is an abominable sight ... worse things to come. // ,Rothwell and colleague ... warn that fat around the abdomen is enemy to ... fat cells has an adverse effect on the heart. ...
... published in the Journal of Vertebral Subluxation Research ... benefits //to children suffering from learning disabilities and ... Swiss chiropractor Yannick Pauli, DC, president of the ... care of children suffering from learning and behavioral ...
... patients who were affected by parasitic infections had a ... Sclerosis is an auto immune disease which harms the ... ,Jorge Correale and Mauricio Farez of the Raul Carrea ... information, in the Annals of Neurology. A study was ...
... has entered the fray of painkillers, especially the likes of ... soreness after a heavy work out or exercise. A new ... of coffee, consumed before a work out, may ease muscle ... Patrick O'Connor, of the department of kinesiology at the University ...
... to human community by killing around 50 million people across ... the affected bodies exhibited a strange type of reaction //wherein ... to the person affected. ,American researchers reconstructed this ... lungs of the monkeys were damaged within a week. A ...
Cached Medicine News:Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 2Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 3Health News:Work-outs, Not So Much of a ‘pain’ With Caffei 2
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: